You are here

  • Home
  • Archive
  • Volume 73, Issue 6
  • Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis

Article info

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis

Authors

  • Lihi Eder University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Arane Thavaneswaran University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Vinod Chandran University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  • Dafna D Gladman University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Dafna Gladman, University of Toronto Psoriatic Arthritis Clinic, Centre for Prognosis Studies in the Rheumatic Diseases 1E-410B, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8; dafna.gladman{at}utoronto.ca
View Full Text

Citation

Eder L, Thavaneswaran A, Chandran V, et al
Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis
Annals of the Rheumatic Diseases 2014;73:1007-1011.

Publication history

  • Accepted April 1, 2013
  • First published April 25, 2013.
Online issue publication 
October 25, 2017

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions